A Multi-Center, Single-Arm, Open-Label Phase 1b Study of a Novel FGFR3 Inhibitor (B-701) Combined With Pembrolizumab in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma Who Have Progressed Following Platinum-based Chemotherapy

Trial Profile

A Multi-Center, Single-Arm, Open-Label Phase 1b Study of a Novel FGFR3 Inhibitor (B-701) Combined With Pembrolizumab in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma Who Have Progressed Following Platinum-based Chemotherapy

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Jul 2017

At a glance

  • Drugs B 701 (Primary) ; Pembrolizumab
  • Indications Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms U22
  • Sponsors BioClin Therapeutics
  • Most Recent Events

    • 20 Apr 2017 Status changed from planning to recruiting.
    • 12 Aug 2015 New trial record
    • 10 Aug 2015 According to a company media release, BioClin Therapeutics plans to initiate this study by late 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top